Roxana Reyes - Concepedia

Author

Roxana Reyes

Also Known As

D Pinato, Elia Segui, Irina Earnshaw, Javier Marco-Hernández, Jorge Alberto Pérez Hernández, Palma Dileo, R S Reyes, R. Reyes, R. Sánchez Reyes, Rachel Sharkey

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Hospital Clínic de Barcelona Consorci Institut D'Investigacions Biomediques August Pi I Sunyer Institut Gustave Roussy Institut Català d'Oncologia Hôpital Européen Georges-Pompidou

About

Roxana Reyes is an author at Hospital Clínic de Barcelona specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	237
2	Health Sciences	1	1	38
3	Public Health	1	1	30
4	Epidemiology	1	1	30
5	Immunology	1	1	30

Roxana Reyes

Publications

344

Citations

H-Index

Page 1

	Year	Citations
Time-Dependent COVID-19 Mortality in Patients With Cancer Mark Bower, Ramón Salazar, Alexia Bertuzzi, JAMA Oncology	2021	70
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations Mariona Riudavets, Édouard Auclin, Miguel Mosteiro, European Journal of Cancer MedicinePathologyCancer GenomicsBronchial NeoplasmDurvalumab Consolidation	2022	52
EBUS-TBNA Cytological Samples for Comprehensive Molecular Testing in Non–Small Cell Lung Cancer Roberto Martin-Deleon, Cristina Teixidó, Carmen M. Lucena, Cancers Viable BiopsyAdvanced Lung DiseasePathologyClinical GuidelinesTumor Biology	2021	38
MA03.08 Impact of COVID-19 Pandemic in the Diagnosis and Prognosis of Lung Cancer Roxana Reyes, Rafael López Castro, Édouard Auclin, Journal of Thoracic Oncology MedicineMa03.08 ImpactCovid-19 PandemicInfectious Respiratory DiseaseCovid-19 Epidemiology	2021	30
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer David J. Pinato, Daniela Ferrante, Roser Fort‐Culillas, European Journal of Cancer VaccinationVaccine SafetyCovid-19 PandemicImmunologySars-cov-2 Protects	2022	30
Multiplex RNA‐based detection of clinically relevant <i>MET</i> alterations in advanced non‐small cell lung cancer Cristina Aguado, Cristina Teixidó, Ruth Román, Molecular Oncology Tumor BiologyMultiplex TechnologyMet AmplificationOncogenic AgentMedicine	2020	22
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study Nicolas Epaillard, José Carlos Benítez, Teresa Gorría, Lung Cancer Advanced Lung DiseaseMedicinePathologyPleural EffusionPluie Study	2021	22
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry Alessio Cortellini, Alessandra Gennari, Fanny Pommeret, JNCI Journal of the National Cancer Institute	2022	22
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer Édouard Auclin, José Carlos Benítez, Marco Tagliamento, Lung Cancer MedicinePathologyBronchial NeoplasmImmune Checkpoint InhibitorSecond-line Treatment Outcomes	2023	22
Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report Roxana Reyes, Clara Mayo‐de‐las‐Casas, Cristina Teixidó, Clinical Lung Cancer Tumor BiologyBraf/mek InhibitionMedicinePathologyBronchial Neoplasm	2019	21

Page 1